Effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts from the same systemic sclerosis patients: an in vitro assay
Abstract Background Systemic sclerosis (SSc) is characterized by vasculopathy and progressive fibrosis. CTLA4-Ig (abatacept) is able to interact with the cell surface costimulatory molecule CD86 and downregulate the target cell. The aim of this study was to evaluate the in-vitro effects of CTLA4-Ig...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-07-01
|
| Series: | Arthritis Research & Therapy |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13075-018-1652-6 |
| _version_ | 1831730297159286784 |
|---|---|
| author | Maurizio Cutolo Stefano Soldano Paola Montagna Amelia Chiara Trombetta Paola Contini Barbara Ruaro Alberto Sulli Stefano Scabini Emanuela Stratta Sabrina Paolino Carmen Pizzorni Vanessa Smith Renata Brizzolara |
| author_facet | Maurizio Cutolo Stefano Soldano Paola Montagna Amelia Chiara Trombetta Paola Contini Barbara Ruaro Alberto Sulli Stefano Scabini Emanuela Stratta Sabrina Paolino Carmen Pizzorni Vanessa Smith Renata Brizzolara |
| author_sort | Maurizio Cutolo |
| collection | DOAJ |
| description | Abstract Background Systemic sclerosis (SSc) is characterized by vasculopathy and progressive fibrosis. CTLA4-Ig (abatacept) is able to interact with the cell surface costimulatory molecule CD86 and downregulate the target cell. The aim of this study was to evaluate the in-vitro effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts isolated from the same SSc patient. Methods Circulating fibrocytes and skin fibroblasts were obtained from eight SSc patients with “limited” cutaneous involvement and from four healthy subjects (HSs). Samples were analyzed by fluorescence-activated cell sorter analysis (FACS) at baseline (T0) and after 8 days of culture (T8) for CD45, collagen type I (COL I), CXCR4, CD14, CD86, and HLA-DRII expression. Circulating fibrocytes were treated for 3 h and skin fibroblasts for 24/48 h with CTLA4-Ig (10, 50, 100, 500 μg/ml). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed for CD86, COL I, FN, TGFβ, αSMA, S100A4, CXCR2, CXCR4, CD11a, and Western blotting was performed for COL I and FN. Results Using qRT-PCR, the T8-cultured SSc circulating fibrocytes which had not been treated with CTLA4-Ig showed higher gene expression for CD86, αSMA, S100A4, TGFβ, and COL I compared with HS circulating fibrocytes. Interestingly, αSMA/COL I gene expression was significantly lower only in the SSc circulating fibrocytes treated with CTLA4-Ig for 3 h (p < 0.01, p < 0.05). On the contrary, no effects were observed for either SSc or HS skin fibroblasts after CTLA4-Ig treatment. COL I and FN protein expression was unchanged in both SSc and HS skin fibroblasts by Western blot. Conclusions Circulating fibrocytes seem to be more responsive to CTLA4-Ig treatment than skin fibroblasts from the same SSc patient, likely due to their higher expression of CD86. CTLA4-Ig treatment might downregulate the fibrotic process in SSc patients by downregulating the fibrocytes, circulating progenitor cells. |
| first_indexed | 2024-12-21T09:42:41Z |
| format | Article |
| id | doaj.art-8fb2d27c8780487180edfa49ae8eb1c2 |
| institution | Directory Open Access Journal |
| issn | 1478-6362 |
| language | English |
| last_indexed | 2024-12-21T09:42:41Z |
| publishDate | 2018-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Arthritis Research & Therapy |
| spelling | doaj.art-8fb2d27c8780487180edfa49ae8eb1c22022-12-21T19:08:25ZengBMCArthritis Research & Therapy1478-63622018-07-012011910.1186/s13075-018-1652-6Effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts from the same systemic sclerosis patients: an in vitro assayMaurizio Cutolo0Stefano Soldano1Paola Montagna2Amelia Chiara Trombetta3Paola Contini4Barbara Ruaro5Alberto Sulli6Stefano Scabini7Emanuela Stratta8Sabrina Paolino9Carmen Pizzorni10Vanessa Smith11Renata Brizzolara12Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, IRCCS San Martino Polyclinic HospitalResearch Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, IRCCS San Martino Polyclinic HospitalResearch Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, IRCCS San Martino Polyclinic HospitalResearch Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, IRCCS San Martino Polyclinic HospitalDivision of Clinical Immunology, Department of Internal Medicine, University of GenoaResearch Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, IRCCS San Martino Polyclinic HospitalResearch Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, IRCCS San Martino Polyclinic HospitalOncologic Surgery, Department of Surgery, IRCCS San Martino PolyclinicOncologic Surgery, Department of Surgery, IRCCS San Martino PolyclinicResearch Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, IRCCS San Martino Polyclinic HospitalResearch Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, IRCCS San Martino Polyclinic HospitalDepartment of Rheumatology, Ghent University Hospital, Ghent UniversityResearch Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, IRCCS San Martino Polyclinic HospitalAbstract Background Systemic sclerosis (SSc) is characterized by vasculopathy and progressive fibrosis. CTLA4-Ig (abatacept) is able to interact with the cell surface costimulatory molecule CD86 and downregulate the target cell. The aim of this study was to evaluate the in-vitro effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts isolated from the same SSc patient. Methods Circulating fibrocytes and skin fibroblasts were obtained from eight SSc patients with “limited” cutaneous involvement and from four healthy subjects (HSs). Samples were analyzed by fluorescence-activated cell sorter analysis (FACS) at baseline (T0) and after 8 days of culture (T8) for CD45, collagen type I (COL I), CXCR4, CD14, CD86, and HLA-DRII expression. Circulating fibrocytes were treated for 3 h and skin fibroblasts for 24/48 h with CTLA4-Ig (10, 50, 100, 500 μg/ml). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed for CD86, COL I, FN, TGFβ, αSMA, S100A4, CXCR2, CXCR4, CD11a, and Western blotting was performed for COL I and FN. Results Using qRT-PCR, the T8-cultured SSc circulating fibrocytes which had not been treated with CTLA4-Ig showed higher gene expression for CD86, αSMA, S100A4, TGFβ, and COL I compared with HS circulating fibrocytes. Interestingly, αSMA/COL I gene expression was significantly lower only in the SSc circulating fibrocytes treated with CTLA4-Ig for 3 h (p < 0.01, p < 0.05). On the contrary, no effects were observed for either SSc or HS skin fibroblasts after CTLA4-Ig treatment. COL I and FN protein expression was unchanged in both SSc and HS skin fibroblasts by Western blot. Conclusions Circulating fibrocytes seem to be more responsive to CTLA4-Ig treatment than skin fibroblasts from the same SSc patient, likely due to their higher expression of CD86. CTLA4-Ig treatment might downregulate the fibrotic process in SSc patients by downregulating the fibrocytes, circulating progenitor cells.http://link.springer.com/article/10.1186/s13075-018-1652-6FibrocytesSkin fibroblastsCTLA4-IgSystemic sclerosisConnective tissue disease |
| spellingShingle | Maurizio Cutolo Stefano Soldano Paola Montagna Amelia Chiara Trombetta Paola Contini Barbara Ruaro Alberto Sulli Stefano Scabini Emanuela Stratta Sabrina Paolino Carmen Pizzorni Vanessa Smith Renata Brizzolara Effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts from the same systemic sclerosis patients: an in vitro assay Arthritis Research & Therapy Fibrocytes Skin fibroblasts CTLA4-Ig Systemic sclerosis Connective tissue disease |
| title | Effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts from the same systemic sclerosis patients: an in vitro assay |
| title_full | Effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts from the same systemic sclerosis patients: an in vitro assay |
| title_fullStr | Effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts from the same systemic sclerosis patients: an in vitro assay |
| title_full_unstemmed | Effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts from the same systemic sclerosis patients: an in vitro assay |
| title_short | Effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts from the same systemic sclerosis patients: an in vitro assay |
| title_sort | effects of ctla4 ig treatment on circulating fibrocytes and skin fibroblasts from the same systemic sclerosis patients an in vitro assay |
| topic | Fibrocytes Skin fibroblasts CTLA4-Ig Systemic sclerosis Connective tissue disease |
| url | http://link.springer.com/article/10.1186/s13075-018-1652-6 |
| work_keys_str_mv | AT mauriziocutolo effectsofctla4igtreatmentoncirculatingfibrocytesandskinfibroblastsfromthesamesystemicsclerosispatientsaninvitroassay AT stefanosoldano effectsofctla4igtreatmentoncirculatingfibrocytesandskinfibroblastsfromthesamesystemicsclerosispatientsaninvitroassay AT paolamontagna effectsofctla4igtreatmentoncirculatingfibrocytesandskinfibroblastsfromthesamesystemicsclerosispatientsaninvitroassay AT ameliachiaratrombetta effectsofctla4igtreatmentoncirculatingfibrocytesandskinfibroblastsfromthesamesystemicsclerosispatientsaninvitroassay AT paolacontini effectsofctla4igtreatmentoncirculatingfibrocytesandskinfibroblastsfromthesamesystemicsclerosispatientsaninvitroassay AT barbararuaro effectsofctla4igtreatmentoncirculatingfibrocytesandskinfibroblastsfromthesamesystemicsclerosispatientsaninvitroassay AT albertosulli effectsofctla4igtreatmentoncirculatingfibrocytesandskinfibroblastsfromthesamesystemicsclerosispatientsaninvitroassay AT stefanoscabini effectsofctla4igtreatmentoncirculatingfibrocytesandskinfibroblastsfromthesamesystemicsclerosispatientsaninvitroassay AT emanuelastratta effectsofctla4igtreatmentoncirculatingfibrocytesandskinfibroblastsfromthesamesystemicsclerosispatientsaninvitroassay AT sabrinapaolino effectsofctla4igtreatmentoncirculatingfibrocytesandskinfibroblastsfromthesamesystemicsclerosispatientsaninvitroassay AT carmenpizzorni effectsofctla4igtreatmentoncirculatingfibrocytesandskinfibroblastsfromthesamesystemicsclerosispatientsaninvitroassay AT vanessasmith effectsofctla4igtreatmentoncirculatingfibrocytesandskinfibroblastsfromthesamesystemicsclerosispatientsaninvitroassay AT renatabrizzolara effectsofctla4igtreatmentoncirculatingfibrocytesandskinfibroblastsfromthesamesystemicsclerosispatientsaninvitroassay |